Latest News

(UroToday.com) Collecting duct renal cell carcinoma is a rare and aggressive form of kidney cancer that is often misdiagnosed, lacks standard treatment protocols, and is poorly characterized at the molecular level. There are at least two molecular subtypes that have recently been uncovered, based on RNA expression of cell signaling, metabolic and immune-related genes.1

(UroToday.com) Petros Grivas (Seattle Cancer Care Alliance) chaired the first session of the 7th Annual Leo and Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR) Symposium on immuno-oncology, setting the scene for the role of immunotherapy (IO) in urothelial cancer (UC) by summarizing recent advances and outlining unanswered questions.

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Nieves Martinez Chanza discussing results of avelumab as neoadjuvant therapy in platinum eligible and ineligible patients with muscle-invasive bladder cancer (MIBC). Cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy is considered as standard of care for non-metastatic […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Matthew Galsky discussing results of cisplatin-related immunomodulation and efficacy with atezolizumab + cisplatin versus carboplatin-based chemotherapy in metastatic urothelial cancer. Cisplatin but not carboplatin-based chemotherapy leads to durable disease control in a subset of patients with […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Jeroen Van Dorp discussing results of NABUCCO Cohort 2 assessing high- versus low-dose pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer. The prognosis of stage III (cT3-4aN0M0 or cT1-4aN1-3M0) urothelial carcinoma is poor, with a […]

(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer mini-oral session included a presentation by Dr. Giuseppe Procopio discussing results from the phase 2 BONSAI trial. 

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Neeraj Agarwal presented results of the COSMIC-021 cohort 6, examining the role of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Shahneen Sandu presented the preliminary results based on an interim analysis of the PRINCE trial assessing the role of 177-Lu-PSMA-617 in combination with pembrolizumab in men with metastatic castration-resistant prostate cancer (mCRPC).

(UroToday.com) Following the presentation from Neeraj Agarwal of the results of expanded cohort 6 of the COSMIC-021 Study utilizing cabozantinib + atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC), Cora Sternberg provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress […]

(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Andrew Armstrong presented the final overall survival analysis from the ARCHES trial of enzalutamide in men with metastatic hormone-sensitive prostate cancer (mHSPC).